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SUMMARY 
 
Hereditary transthyretin amyloidosis (ATTR) is a rare worldwide autosomal dominant disease 
caused by a single amino acid substitution in the transthyretin (TTR) gene. The most common 
mutation is V30M, typical of the Portuguese patients. Each variant has a different involvement, 
although peripheral neuropathy and cardiomyopathy are the most common. Liver 
transplantation was implemented as the inaugural disease-modifying therapy since the liver 
produces the circulating unstable TTR. 
In this review, we focus the results and long-term outcomes of liver transplantation in ATTR 
after 2063 procedures and 23 years of experience. Nerve and organ impairment did not usually 
reverse after successful transplantation and, in some cases, the disease progressed. Mortality 
and morbidity are related with later-onset particularly in males, malnutrition and 
cardiomyopathy. The mutation type, non-TTR V30M, and deposits composed by a mixture of 
truncated and full-length TTR are associated with lower survival. A higher incidence of early 
hepatic artery thrombosis of the graft was also documented. The sequential procedure, ATTR 
livers reused in patients with liver disease, demonstrated that de novo ATTR amyloidosis may 
appear earlier than expected.  
Long-term results of trials with amyloid protein stabilizers or disrupters, silencing-RNA and 
antisense oligonucleotides will highlight the value and limitations of liver transplantation.  
 
 
Keywords: transthyretin, amyloid, liver transplant, neuropathy, cardiomyopathy. 
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INTRODUCTION 
Transthyretin (TTR) is a soluble plasmatic transporter of thyroxine and retinol-binding 
protein. It presents a native tetrameric structure that, in the presence of an amyloidogenic 
mutation, is more unstable and prone to dissociation into monomers. These are susceptible to 
misfolding and self-aggregation in insoluble amyloid fibrils capable of systemic extracellular 
deposition [1,2]. Usually amyloidosis is not evident until adulthood, probably reflecting the 
influence of non-genetic factors, such as those associated with the ageing process [3]. There is 
a greater susceptibility to fibrinogen glycation, impairing its chaperone activity and therefore 
the TTR tetramer stability [4]. To date, more than 120 mutations of the single gene encoding 
TTR are described in the literature [2,3] and approximately 13 are non-amyloidogenic [5,6]. 
The disease phenotype is variable according to the genotype, although a clear 
genotypic/phenotypic relationship is absent [1,6]. The worldwide most common mutation, TTR 
V30M - substitution of methionine for valine at position 30, has main foci in Portugal, Sweden 
and Japan [1,7]. It predominantly gives rise to an autosomal-dominant neuropathy first 
described by Corino de Andrade as Portuguese type Familial Amyloidotic Polyneuropathy (TTR-
FAP) [6,8]. This sensorimotor polyneuropathy usually begins with sensitive disorders in the 
lower extremities, like dissociated anesthesia and paresthesia, which show an upward 
progression. The autonomic involvement also manifests early, by gastrointestinal disturbances, 
orthostatic hypotension, neurogenic bladder or erectile dysfunction. Motor dysfunction 
commonly occurs within a few years [1,8]. Although, other organs such as heart, 
gastrointestinal tract and kidneys can be affected, demonstrating the disease systemic nature 
[1,6]. TTR-FAP relentlessly progresses and becomes extremely disabling, with patients losing 
their walking capacity, experiencing malnutrition, life-threatening autonomic dysfunction and 
finally death [6]. Familial Amyloidotic Cardiomyopathy is another relatively common 
phenotype of hereditary TTR amyloidosis (ATTR), characterized by an infiltrative 
cardiomyopathy with involvement of the conduction system, and usually associates with some 
non-TTR V30M mutations [1,3,7].  
The diagnosis is based on identification of TTR mutation, suggestive clinical picture and 
histological evidence of TTR amyloid deposits, since ATTR has incomplete penetrance. The 
definitive diagnosis is established by tissue biopsy, however this has a significant risk of false-
negative outcomes owing to the patchy pattern of amyloid deposition [1,6]. In non-endemic 
areas the diagnosis can be even more difficult once the ATTR generally manifests without 
familial antecedents [1,6,7] and possibly by atypical features like ataxia or upper limb onset 
neuropathy [9]. Distinct geographic groups vary in penetrance, age at onset, symptoms and 
survival, even for the same TTR mutation [1,2,6]. Early-onset ATTR V30M usually occurs in 
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Portuguese and Japanese patients around the third decade of life; onset in the fifth decade is 
typical in Swedish cases. The bimodal age at onset may be correlated with the composition of 
TTR fibrils [2,6,10] and the presence of anti-TTR V30M antibodies  [9]. 
Liver transplantation suppresses the production of circulating mutant TTR and 
theoretically stops the amyloid formation and disease progression, since most of TTR has 
hepatic origin [2,6]. Epithelial cells of the choroid plexus and the retinal pigment epithelium 
also express TTR. Therefore, several genotypes may have leptomeningeal and ocular 
involvement like vitreous opacities, probably due to locally produced TTR [1,3]. 
In this review, we focus the current knowledge about orthotopic liver transplantation 
(OLT). It also addresses combined liver-heart/kidney transplantation, the controversies around 
sequential liver transplantation and novel therapeutic approaches for ATTR. 
 
ORTHOTOPIC LIVER TRANSPLANTATION FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS 
Historical Perspective 
The inaugural OLT for ATTR was performed in 1990 [11]. Previously the disease 
management was based only in symptomatic treatment without any improvement in overall 
survival. Thus, OLT was expected to be a disease-modifying and curative procedure [1,12].  
By the time of the first Workshop in Liver Transplantation for FAP (1993), OLT became 
an accepted treatment for TTR-FAP, since the outcomes were encouraging [11,13]. According 
to FAP World Transplant Registry (FAPWTR, http://www.fapwtr.org), until 31 December 2012, 
a total of 2063 patients with ATTR underwent OLT, performed in 77 centers from 19 countries. 
 
Prognostic predictors after orthotopic liver transplantation 
After 23 years of cumulative experience is consensual that the major prognostic factors 
are: 
Age at liver transplantation - advanced age is an independent risk factor for late mortality [14-
17]. Late-onset disease tends to be associated with lower post-transplant survival [18] and 
with progressive cardiomyopathy, especially in males with TTR V30M [19]. This seems to be 
related with age-dependent modifications in extracellular matrix components and deposition 
of a different type of amyloid fibrils [20].  
Duration of disease - OLT performed in long-standing disease (≥7 years) is associated with 
inferior survival and quality of life (QOL) [6,17,21-25]. 
Pre-transplant clinical status - peripheral neuropathy does not seem to be correlated with 
mortality [14,26,27]. It has main impact in QOL since the pre-transplant symptoms usually do 
not regress significantly [5,6,28]. Autonomic dysfunction however increases the surgical risk 
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due to intraoperative circulatory instability and may be associated with late sudden death, 
probably potentiated by life-threatening arrhythmias [6,14,29,30]. In Portuguese type patients, 
myocardial sympathetic denervation assessed by 123-iodine metaiodobenzylguanidine (123I-
MIBG) imaging is an independent prognostic predictor. Late heart-to-mediastinum 123I-MIBG 
uptake ratio <1.60 is associated with higher neurological disability and mortality, although they 
apparently still benefit from OLT [31]. Okamoto et al. [32] propose a possible correlation 
between pre-transplant cardiomyopathy and post-transplant survival, with 10-years survival 
rates of 92% and 64%, respectively for patients without and with cardiomyopathy.  
Preoperative nutritional status - severe malnutrition is associated with higher mortality and 
OLT does not improve the prognosis [22]. Modified body mass index (mBMI) is remarkable in 
predicting post-transplant morbidity and survival that is better in patients with mBMI >600, 
compared to patients not undergoing OLT [18]. mBMI shows a strong correlation with duration 
of disease and, as an objective measure, allows more accurately survival comparisons [14]. 
Type of transthyretin mutation - OLT performed for/in non-TTR V30M cases is associated with 
lower 5-year survival rate [33]. There are also several records of amyloidosis progression in 
these patients [19,30,34,35].  
Composition of transthyretin fibrils - patients with a mixture of truncated and full-length TTR 
(type A) appear to be more prone to post-transplant development or progression of 
cardiomyopathy and heart failure, compared to the ones with type B fibrils (only full-length 
TTR). Hereafter, this histopathological criterion can assume a relevant role in patient selection 
[36]. 
Despite all of these predictive factors for OLT outcomes and their importance in 
optimizing patient selection, establish the prognosis for a specific patient is still a challenge. 
 
Indications and timing of referral for orthotopic liver transplantation 
Patients with symptomatic TTR-FAP are the most common candidates for OLT. 
Asymptomatic carriers have no indication to OLT, since they may never develop the disease 
[1,6,29]. Mildly symptomatic patients may be deprived of living a few years with good QOL 
when submitted to OLT since it implies specific cares, like immunosuppression [18]. 
After clinical stabilization with symptomatic treatment, a selection of transplant 
candidates should be done according to the prognostic factors mentioned [1]. Suhr et al. [29] 
defined some unsuitable candidates for OLT - patients with severe neuropathy, particularly if 
they have hand dysfunction or pronounced risk for circulatory instability; cases of 
cardiomyopathy with late-onset or in elderly, especially if male, or in patients with type A 
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fibrils; patients with long-standing disease and mBMI <600. Moreover, OLT seems to be an 
inadequate treatment for patients with an oculoleptomeningeal phenotype [37-39].  
To optimize post-transplant survival and QOL, the referral for OLT should be done 
immediately after the diagnosis establishment and ideally in initial phases of the disease, 
particularly stage I (walking unaided) and sometimes early stage II disease (walking with 
assistance) [1,6,21-24,40]. However, the challenge of early diagnosis and the prolonged 
waiting time on the transplant list, can be an obstacle to this goal. Besides that, the rate of 
symptomatic progression is unpredictable due to high inter-individual variability [1,6,14]. 
 
Outcomes of orthotopic liver transplantation 
Overall patient survival rate: Natural average life expectancy is 9-13 years after the 
symptomatic presentation and death usually is secondary to cardiac involvement or cachexia 
[6,10]. The value of OLT in prolonging survival beyond that expected from the natural course of 
ATTR was demonstrated [16,41]. Five-year survival figures evolved from 78% in 2001 [42] to 
more than 90% [29] or even 100% [7] at experienced centers. Additionally there are more 
reports of excellent survival with a 10-year survival estimated probability of 100% compared to 
56,1% in non-transplanted patients [41]. These results are probably the reflection of 
accumulated experience, better patient selection, earlier referral to OLT, recognition of the 
peculiarity of these patients, prevention and management of intraoperative and 
posttransplant specific complications [14,17]. However, these statistics are mostly related to 
patients with ATTR V30M. According to FAPWTR [33], the 5-year survival rate was 59% for 
non-ATTR V30M patients against 82% for V30M. 
 Clinicopathological outcomes: Early experience suggested symptomatic improvement 
as the rule [13,21,43,44], but nowadays it is consensual that the natural steadily clinical 
deterioration is halted in most of transplanted patients. Therefore, main pre-transplant 
symptoms will still be present after transplantation [14,17,24,35,40,45,46]. Although some 
patients may manifest symptomatic improvement or deterioration [12,17,29,47]. The latter is 
most likely in patients presenting poor prognostic factors [12]. Results vary in accordance with 
the specific symptoms evaluated (table 1), like cardiovascular manifestations that tend to 
progress [30]. It has been hypothesized that there is a point of progression of the disease from 
which there are no regression, possibly because of irreversible organ injury, reinforcing the 
need for early transplantation [1,35,48]. 
After OLT, mutant TTR is rapidly cleared from circulation [11], since it has a brief 
plasma half-life (2.1 days) [44] and there is no consistent evidence that extra-hepatic sources 
of TTR contribute to its plasmatic pool [2]. Regression of visceral amyloid deposits, evidenced 
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by serum amyloid P component scintigraphy and acompained by symptomatic improvement, 
was seen in 2 of the first transplanted patients [13], but without histological evidence of it. In a 
series of 6 transplanted patients with ATTR V30M, all showed reduction or disappearance of 
amyloid deposits in sequential abdominal fat aspirates more than 10 years after OLT, even in a 
patient with disease progression [47]. Remains the question regarding which is the amyloid 
status of the main target organs. Currently it is believed that the most probable post-
transplant outcome is no significant reduction of amyloid deposits [1,45,49], with some 
reports of ongoing amyloid deposition, essentially at cardiac tissue (Figure 1) and in cases of 
non-ATTR V30M [12,19,24,30,34,50-52]. Although less significant, there may be amyloidosis 
progression in other organs [52] (Table 1). 
As evidenced by senile systemic amyloidosis, an age-related TTR amyloidosis 
predominantly manifested by cardiomyopathy, wild-type TTR is capable of amyloid deposition, 
demonstrating an inherent amyloidogenic capacity [2,6,10,35]. Thus, amyloidogenesis can 
persist even in the absence of mutant TTR, apparently by deposition of wild-type TTR on a 
substrate of pre-existing amyloid fibrils [2,6,47,53], especially with type A fibrils [36].  
Opposite to end-stage liver disease, the post-transplant improvement is less 
recognizable in patients with ATTR since they usually have fewer pre-transplant symptoms and 
this major surgery does not guarantee their regression. The patient must be advised that the 
aim of OLT is prevent additional deterioration and new complications [6,17,48]. 
Quality of life: As this is a progressively disabling disease, the goal of OLT goes beyond 
the mortality reduction. However, this has fallen short of expectations when comparing to liver 
transplanted patients for other causes, probably due to post-transplant persistence of 
symptoms [54,55]. 
Cause of death: In the OLT era, death from cardiac disease acquired greater 
representation comparatively to historical causes of death like cachexia, infections or 
cardiovascular collapse [8]. Recent data from FAPWTR points out for 45% of post-transplant 
deaths from cardiac causes or septicemia. To prevent this outcome, post-transplant follow-up 
of all ATTR cases, especially in aging patients due to their greater risk for cardiomyopathy 
progression, must include a periodic echocardiogram and Holter ECG [17,35,38,51]. Okamoto 
et al. [56] also proposed serial evaluations of serum BNP. ATTR patients are more susceptible 
to early post-transplant thrombotic complications, in particular to hepatic artery thrombosis 
that correlates with high morbidity [57]. 
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Sequential Liver Transplantation 
Also known as domino liver transplantation (DLT), it consists in transplanting the 
explanted ATTR liver into a selected non-ATTR patient. This is feasible since ATTR gathers the 
essential conditions: the liver is anatomically and functionally normal, despite being the major 
source of mutant TTR, with scarce amyloid deposits and circumscribed to portal vessels and 
hilar nerves (Figure 2)  [58]; has a long latent time before the clinical onset, at least 20 years 
[59]. Furthermore, as a living graft, the ischemic time is very short and thus the likelihood of 
graft dysfunction decreases [60]. 
It was first performed in 1995 in Portugal, by Furtado et al. [59], in order to face the 
disproportionate supply of deceased organ donors and the rising waiting list for OLT. The initial 
DLT recipients were patients with unresectable primary or metastatic liver cancers, with no 
extrahepatic spread and short life expectancy. The safety and successful short-term results for 
both DLT donors and recipients allowed a worldwide acceptance [59-61]. The last update of 
Domino Liver Transplant Registry (DLTR) displays a total of 1085 DLT performed, with ATTR 
patients as the main donors. 
However, the main pitfall of DLT is the risk of the recipient develops de novo ATTR, 
since circulating mutant TTR is soon after detected. Thus the need for a close follow-up with 
monitorization of clinical signs was early recognized [58,59,61]. 
Despite the hope that the disease would take at least 30 years to develop, based on 
the natural history of ATTR [59], the first report of symptomatic systemic TTR amyloidosis in a 
DLT recipient occurred after 8 years of follow-up [62]. However, subclinical skin and nerve 
amyloid deposits were found 3 and 6 years after DLT, respectively [63]. Electrophysiological 
signs of progressive peripheral polyneuropathy without clinical symptoms were also detected 
2-5 years after DLT, however the definitive diagnosis by nerve biopsies couldn’t be established 
[64]. 
Recently, cases of sensory neuropathy of the lower limbs without autonomic 
involvement, occurring as early as 6-7 years after transplant, have been published [65-70]. 
Possible explanations for this accelerated amyloidogenesis are related to age factors since the 
clinical onset in the cases mentioned varied between 55 and 75 years. However, Obayashi et 
al. [70] described a case of TTR amyloidosis in a 45-year-old man with primary sclerosing 
cholangitis that underwent DLT 10 years before. Other potential justifications are surgical 
trauma, immunosuppression and inflammatory reactions related to graft rejection or 
reactivation of latent viruses [71]. The clinical onset of TTR amyloidosis in DLT recipients has 
generally been considered an indication for retransplantation with a non-ATTR liver [61,62,64]. 
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Its efficacy in halting the disease progression is now starting to be reported, with one case of 
partial symptomatic recovery [72]. Futurely, pharmacologic treatment may also have a role. 
Ericzon et al. [71] advocates that DLT should continue since the ATTR liver can still be 
an excellent graft when a case by case risk-benefit assessment is done. Other experts [66-
68,70] reinforce this idea and the need for the future DLT recipient to give a truly informed 
consent and to be regularly monitored for de novo TTR amyloidosis. Recently, Bolte et al. [69] 
proposed a scheme for neurologic follow-up of these patients based on periodic assessment of 
specific scores of peripheral neuropathy, quantitative sensory testing, nerve conduction 
studies and sural nerve biopsy performed only in patients with ≥2 alterations in the previous 
tests. According to these findings and the possibility of neuropathy from other etiologies, an 
estimate of the relative probability of de novo TTR amyloidosis is made. 
 
Multiple Organ Transplantation  
According to the FAPWTR, among 2063 reported transplants, there were 46 
simultaneous heart-liver transplants and 47 simultaneous liver-kidney transplants. Only 4 were 
combined heart-liver-kidney transplants. 
The first worldwide Combined Heart-Liver Transplantation (CHLT) for ATTR dates back 
beyond 1993 [73] and the following reports show that all of them were performed in non-TTR 
V30M cases [74-76]. This can be explained by their higher and earlier predisposition to 
cardiomyopathy, that can progress even after successful OLT [30]. Thus they represent the 
main candidates for this procedure [12,74,75]. Outcomes of CHLT have been adversely 
influenciated by the preoperative clinical status. However, they seem to be encouraging since 
histological and imagiological evidences of amyloid deposits have not been found yet [74,75]. 
Nevertheless, the hypothesis of progressive neurological disability after CHLT remains [74]. 
Combined liver-kidney transplantation (CLKT) is indicated in patients with end-stage 
renal disease, since renal replacement therapy correlates with poor survival. Moreover, 
isolated OLT in patients with a preoperative glomerular filtration rate <30mL/min is associated 
with a significant postoperative deterioration of kidney function [77,78]. A series of 13 patients 
with different indications for CLKT, including 3 patients with FAP, reinforced the idea that the 
liver graft may have a protective immunologic effect on the kidney graft [79]. Lobato et al. [77] 
reported the absence of proteinuria and a mean serum creatinine in the superior limit of the 
reference interval after 84 months of follow-up of 6 patients with ATTR V30M submitted to 
CLKT. These results suggest that CLKT prevents the recurrence of nephropathy, although 
without histologic evidence of it, but not the progression of polyneuropathy, as expected. 
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NOVEL THERAPEUTIC APPROACHES 
 The persistent searching for an ideal therapy to ATTR began too many years ago and it 
still continues today with a preference towards less invasive options, since the current ones 
have imperfections or need more time of experience to evaluate the long-term outcomes. 
 The partial understanding of TTR amyloidogenesis has allowed the development of 
several potencial new treatments acting in different phases of the process (Table 2). Further 
progresses in that area are expected due to recent success in generation of ATTR-specific 
induced pluripotent stem cells [80]. Nowadays the most promising drugs seem to be the TTR 
stabilizing agents. They prevent amyloidogenesis by inhibiting the TTR tetramer dissociation 
and include the first medical treatment specifically approved to TTR-FAP in Europe in 2011 - 
tafamidis meglumine. This drug has shown capacity to slow down the progression of early 
stages of peripheral neuropathy and therefore is formally indicated for patients with the 
neuropathic form of ATTR in stage I, regardless of the type of mutation [1,10]. Nevertheless 
there is evidence that suggests less efficacy in halting neurological dysfunction in non-TTR 
V30M mutations. Patients with late-onset ATTR V30M involved in a non-randomized 
controlled trial showed disability progression in 55% of cases and increased Neuropathy 
Impairment Scores in most of them [9]. Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
capable of stabilize the TTR tetramer since their structure resembles the one of thyroxine, that 
is the main responsible for tetramer stabilization. Diflunisal is already in clinical trials with the 
actual concerns being the therapeutic serum concentrations, the adverse effects profile and its 
efficacy in other phenotypes of ATTR [1,10]. An open-label uncontrolled trial was conducted 
with 13 patients presenting symptomatic and biopsy-proven ATTR cardiomyopathy. They were 
medicated with diflunisal (250mg bid) for a mean of 10.8 months, during which no significant 
changes in cardiac structure function and biomarkers were observed. Diflunisal seems to have 
potential to slow the disease progression, although needs careful renal and hematologic 
monitoring. These results require confirmation in a randomized placebo-controlled trial [81]. 
Several agents are presently under investigation, with some yet restricted to preclinical 
studies. A recent article about clinical management of ATTR patients expresses the idea that as 
new effective drugs become available they should be offered to patients meeting their clinical 
indications, irrespective of liver transplant plans [1]. 
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DISCUSSION 
More than half century after the first description of this progressively incapacitating 
disease there are still some challenges and unresolved issues, particularly at therapeutic level.  
After 23 years of accumulated experience it is well-known that OLT, the first disease-
modifying therapy, allowed a revolution in ATTR treatment, though it has some limitations. In 
the majority of patients the preexisting symptoms will remain unchanged after OLT and 
besides, it is incapable of alter the natural course of oculoleptomeningeal amyloidosis. Not all 
patients with ATTR are suitable candidates for OLT, therefore the outcomes of this procedure 
have been optimized through a careful patient selection. However is still something missing 
since there are some reports of post-transplant disease progression. Amyloid fibril 
composition may add some insight in outcome prediction. The shortage of liver donors is 
another important restriction, partially relieved by DLT that recently has shown some 
unexpected unfavorable long-term outcomes. There is a need for better understanding of 
possible predisposing factors to systemic TTR amyloidosis in DLT recipients, like early-onset 
disease or non-TTR V30M mutations in DLT donors. Furthermore, OLT is an invasive therapy 
with significant surgical risk and requires long-standing immunosuppression. Consequently, 
OLT is not approved for asymptomatic patients with TTR amyloid deposits (stage 0 of disease). 
Current therapeutic options for ATTR are still limited, but recently expanded with 
another disease-modifying therapy - tafamidis. The approval of this drug in Europe has raised 
several unanswered questions such as its efficacy in the treatment of amyloid cardiomyopathy 
and for patients with stage 0 or advanced stages of disease, for which there is still a gap in 
therapeutic options. The future may validate a combined approach to ATTR, OLT plus drug 
treatment, but for now is still controversial if patients showing improvement under tafamidis 
should remain on the transplant list. Moreover, the hope also rests on the approval of new 
drugs, like the ones capable of amyloid deposits dissolution.  
Is liver transplantation really a life-saving treatment for ATTR? The truth is that OLT, 
besides all the controversies and limitations, has allowed a revolutionary change in survival of 
most patients, but the future about curative treatments is still unwritten. 
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 TABLES
Table 1 - Clinicopathological outcomes 
 Clinical outcomes Histopathological outcomes 
Peripheral 
neuropathy 
- Neurologic dysfunction rarely progresses [13,17,27,40,50]. 
- Sensory disturbances and early stages of disease are more likely to improve [6,17,35].  
- Recovery of peripheral nerve function is rare [40,46].  
- Regression of amyloid deposits in peripheral 
nerves is still uncertain [46]. 
Autonomic 
neuropathy 
- Several reports of autonomic disturbances regression, particularly in ATTR V30M 
[13,30,40,50,82,83]. 
- Improvement of orthostatic hypotension [27,43]. 
- Decrease of gastrointestinal symptoms and improvement in nutritional status [17,21,43,50,84]. 
- Few reports about bladder and erectile dysfunctions which showed variable outcomes [50,85]. 
- Contradictory histological evidence, favoring 
the post-transplant persistence of denervation 
[40]. 
Cardiac 
amyloidosis 
- Several reports of cardiomyopathy progression after successful OLT, predominantly but not 
exclusive for non-ATTR V30M [17,30,34,51,56,86]. 
- Aging also seems to be a risk factor for progression [38]. 
- Does not prevent life-threatening arrhythmias, which seem more prevalent in ATTR V30M 
[38,75,87]. 
- Autopsy findings showed a predominance of 
wild-type TTR in post-transplant cardiac amyloid 
deposits [52,53]. 
Renal 
amyloidosis 
- Stabilization of kidney function after an initial deterioration - controversial [35,38,88,89].  
- Regression, intensification or onset of proteinuria [85]. 
- Other factors can contribute to renal impairment - nephrotoxicity of immunosuppressants, 
kidney damage secondary to neurogenic bladder, diabetes mellitus [6,35]. 
- The rare histopathological reports suggest that 
OLT can prevent further progression of kidney 
amyloidosis [38,86,88]. 
- Biochemical analysis of amyloid kidney deposits 
supports for de novo amyloidogenesis [52]. 
Ocular 
amyloidosis 
- Progression independently of the type of TTR mutation [37-40,50,90]. 
- Aging is a major determinant of this course [38]. 
 
Leptomeningeal 
amyloidosis 
- One report of unsuccessful OLT in two siblings with ATTR Leu12Pro manifested by grand mal 
seizures [75]. 
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Table 2. Potential therapeutic strategies for ATTR according to the model of TTR amyloidogenesis 
Mechanism Potential treatments Considerations 
Substitution of 
mutant TTR gene for 
normal TTR gene 
Liver transplantation#  
Gene therapy (conversion) 
- Single-stranded oligonucleotides* 
Gene therapy to repair the mutant TTR gene has still a long path before it can 
be applied clinically. 
Suppression of TTR 
mRNA expression 
Injection of a large amount of normal TTR 
Significant (but not enough) reduction in mutant TTR plasmatic levels. Clinical 
utility precluded by the rapid turnover of TTR.  
Gene therapy (silencing)*: 
- Small interfering RNA: ALN-TTR01, ALN-TTR02 
- Antisense oligonucleotides: ISIS-TTRRX 
Synthesis inhibition of mutant and wild-type TTR, both with amyloidogenic 
capacity. Induces a dose-dependent and more durable response. Phase 3 
clinical trials. 
Decrease plasmatic 
levels of mutant TTR 
Plasma exchange  
Ineffective in inducing enough decrease of serum TTR. Infeasible due to short 
TTR half-life, implying a continuous treatment. 
Affinity column chromatography 
TTR absorption column chromatography 
Stabilization of the 
TTR tetramer 
Thyroxine-based therapeutic drugs: 
- Tafamidis meglumine (Fx-1006A)# 
- NSAIDs*: diflunisal, diclofenac, flufenamic acid 
The most promising agents for halting the relentless progression of ATTR. 
Trivalent chromium (Cr3+)* Can potentiate the effects of NSAIDs due to its non-competitive action. 
TTR T119M monomers* 
These non-amyloidogenic monomers are incorporated into tetramers making 
them less amyloidogenic. In vitro studies. 
Prevention of 
amyloid formation 
Free radical scavenger therapy (300mg N-acetylcysteine, 300mg 
α-tocopherol and 500mg vitamin C) 
Without effect in non-transplanted patients; slight improvement in the 
nutritional status of transplanted patients. 
Immunization with unstable TTR (TTR Y78F) Clinical application limited by immunization-related inflammation. 
Cyclodextrin* Reduces conformational change of TTR. In preclinical studies. 
Carvedilol* Decreases amyloid deposits due to antioxidant effect. In preclinical studies. 
Dissolution of 
amyloid aggregates 
IDOX (4’-Iodo-4’-deoxydoxorubicin) Lack of in vivo studies. Nephrotoxic. 
Doxy-TUDCA (Doxycycline and tauroursodeoxycholic acid)* Seems to stabilize the disease at least during 1 year. Tolerable adverse effects. 
Anti-SAP (serum amyloid P component) monoclonal antibodies* Phase 1 study in patients with AA amyloidosis. 
Epigallocatechin-3-gallate* In preclinical trials. 
#
 Current available therapies for clinical use. * Therapies with promising future outcomes. Based on Ando et al. [1,28], Araki et al. [7], Hund et al. [10], Lobato et al. [78] and Adams et al. [9]. 
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FIGURE LEGENDS 
 
 
Figure 1 - An example of severe cardiomegaly in a patient with progressive amyloid 
cardiomyopathy after orthotopic liver transplantation (Luísa Lobato, personal archives). 
 
 
Figure 2 - Congo red stained material showing amyloid deposits in the arteriole of the liver in a 
sequential liver receptor from a donor with ATTR V30M-amyloidosis (x400); amyloid spares 
bile ducts (Luísa Lobato, personal archives). 
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10. FIGURE LEGENDS
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COMMON ABBREVIATIONS
ADP adenosine diphosphate
ADPase adenosine diphosphatase
ALT alanine aminotransferase
anti-HAV antibody to hepatitis A virus
anti-HBc antibody to hepatitis B core antigen
anti-Hbe antibody to hepatitis B e antigen
anti-HBs antibody to hepatitis B surface antigen
anti-HCV antibody to hepatitis C virus
anti-HDV antibody to hepatitis D (delta) virus
AST aspartate aminotransferase
ATP adenosine triphosphate
ATPase adenosine triphosphatase
BUN blood urea nitrogen
CAH chronic active hepatitis
CD Crohn’s Disease
CDAI Crohn’s Disease Activity Index
HAV hepatitis A virus
HBcAg hepatitis B core antigen
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus
HDV hepatitis D (delta) virus
H&E hematoxylin and eosin stain
IBD inflammatory bowel disease
Ig immunoglobulin
KICG plasma disappearance rate of indocyanine green
NSAID non-steroidal anti-inflammatory drug
PBS phosphate-buffered saline
RBC red blood cell
RIA radioimmunoassay
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SI saturation index
TPN total parenteral index
UC ulcerative colitis
UNITS
°C degree(s) Celsius
cpm counts per minute
cps counts per second
cm3 cubic centimeter(s)
cycle/min cycles per minute
cycle/s cycles per second
day(s) day(s)
d density
°F degree(s) Fahrenheit
g gram(s)
g gravity, gravities
t½ half-life
Hz hertz
h hour(s)
in inch(es)
IU international unit(s)
K kelvin
kcal kilocalorie(s)
kg kilogram(s)
L liter(s)
mL milliliter(s)
μL microliter(s)
m meter(s)
μm micrometers
x magnification
mile/h mile(s) per hour
mm Hg millimeters of mercury
min minute(s)
Mol/L molar
mo month(s)
mol mole(s)
N normal
oz ounce(s)
lb pound(s)
rpm revolutions per minute
rps revolutions per second
s second(s)
U unit(s)
V volt(s)
W watt(s)
wk week(s)
yr year(s)
STATISTICAL TERMS
χ2 method chi-squared method
r correlation co-efficient
df degrees of freedom
x mean
NS not significant
n number of observations
p probability
SD standard deviation
SE standard error
SEM standard error of the mean
F variance ratio
